These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 26088460)
1. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. Vogelbaum MA; Hu C; Peereboom DM; Macdonald DR; Giannini C; Suh JH; Jenkins RB; Laack NN; Brachman DG; Shrieve DC; Souhami L; Mehta MP J Neurooncol; 2015 Sep; 124(3):413-20. PubMed ID: 26088460 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Vogelbaum MA; Berkey B; Peereboom D; Macdonald D; Giannini C; Suh JH; Jenkins R; Herman J; Brown P; Blumenthal DT; Biggs C; Schultz C; Mehta M Neuro Oncol; 2009 Apr; 11(2):167-75. PubMed ID: 18779504 [TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Thomas AA; Abrey LE; Terziev R; Raizer J; Martinez NL; Forsyth P; Paleologos N; Matasar M; Sauter CS; Moskowitz C; Nimer SD; DeAngelis LM; Kaley T; Grimm S; Louis DN; Cairncross JG; Panageas KS; Briggs S; Faivre G; Mohile NA; Mehta J; Jonsson P; Chakravarty D; Gao J; Schultz N; Brennan CW; Huse JT; Omuro A Neuro Oncol; 2017 Oct; 19(10):1380-1390. PubMed ID: 28472509 [TBL] [Abstract][Full Text] [Related]
4. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide. Speirs CK; Simpson JR; Robinson CG; DeWees TA; Tran DD; Linette G; Chicoine MR; Dacey RG; Rich KM; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):268-76. PubMed ID: 25636755 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576 [TBL] [Abstract][Full Text] [Related]
6. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. Gan HK; Rosenthal MA; Dowling A; Kalnins R; Algar E; Wong N; Benson A; Woods AM; Cher L Neuro Oncol; 2010 May; 12(5):500-7. PubMed ID: 20406900 [TBL] [Abstract][Full Text] [Related]
7. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Cairncross G; Wang M; Shaw E; Jenkins R; Brachman D; Buckner J; Fink K; Souhami L; Laperriere N; Curran W; Mehta M J Clin Oncol; 2013 Jan; 31(3):337-43. PubMed ID: 23071247 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911 [TBL] [Abstract][Full Text] [Related]
11. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Roth P; Wick W; Weller M Curr Treat Options Oncol; 2013 Dec; 14(4):505-13. PubMed ID: 23907441 [TBL] [Abstract][Full Text] [Related]
12. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers. Minniti G; Arcella A; Scaringi C; Lanzetta G; Di Stefano D; Scarpino S; Pace A; Giangaspero F; Osti MF; Enrici RM J Neurooncol; 2014 Jan; 116(2):275-82. PubMed ID: 24162810 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Lecavalier-Barsoum M; Quon H; Abdulkarim B Cochrane Database Syst Rev; 2014 May; 2014(5):CD007104. PubMed ID: 24833028 [TBL] [Abstract][Full Text] [Related]
14. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Wick W; Roth P; Hartmann C; Hau P; Nakamura M; Stockhammer F; Sabel MC; Wick A; Koeppen S; Ketter R; Vajkoczy P; Eyupoglu I; Kalff R; Pietsch T; Happold C; Galldiks N; Schmidt-Graf F; Bamberg M; Reifenberger G; Platten M; von Deimling A; Meisner C; Wiestler B; Weller M; Neuro Oncol; 2016 Nov; 18(11):1529-1537. PubMed ID: 27370396 [TBL] [Abstract][Full Text] [Related]
15. Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? Lassman AB CNS Oncol; 2015; 4(5):341-6. PubMed ID: 26544062 [TBL] [Abstract][Full Text] [Related]
16. Low-grade and anaplastic oligodendroglioma. Van Den Bent MJ; Bromberg JE; Buckner J Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. Chinot OL; Honore S; Dufour H; Barrie M; Figarella-Branger D; Muracciole X; Braguer D; Martin PM; Grisoli F J Clin Oncol; 2001 May; 19(9):2449-55. PubMed ID: 11331324 [TBL] [Abstract][Full Text] [Related]
18. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310 [TBL] [Abstract][Full Text] [Related]
19. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. Rudà R; Pellerino A; Pace A; Carapella CM; Dealis C; Caroli M; Faedi M; Bello L; Migliore E; Marchese G; Bertero L; Cassoni P; Soffietti R J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]